Search results
Results from the WOW.Com Content Network
COVID-19 vaccines gave Moderna, Pfizer and Johnson & Johnson a boost — but are their stocks still good buys in 2021? Here's what to consider before investing. Vaccine Stocks: Are Pfizer, Moderna ...
Stocks fell Wednesday afternoon, reversing earlier gains after new data from Pfizer (PFE) helped momentarily stoke investor confidence that an effective vaccine will become available in the coming ...
The early lead in the vaccine race went to Moderna -- shares skyrocketed in late February when the company announced it would be working on a vaccine alongside the National Institute of Allergy ...
On July 22, 2020, the U.S. government placed a conditional advance-purchase order of $2 billion with Pfizer to manufacture 100 million doses of a COVID-19 vaccine, with an option for 500 million more, for use in the United States if the vaccine was shown to be safe, effective, licensed, and authorized by the Food and Drug Administration (FDA).
As of November 2020, companies subsidized under the United States' Operation Warp Speed program have set initial pricing at US$19.50 to US$25 per dose, in line with the influenza vaccine. [130] In December 2020, a Belgian politician briefly published the confidential prices agreed between vaccine producers and the EU: [131]
On 20 February 2020, stock markets across the world suddenly crashed after growing instability due to the COVID-19 pandemic.It ended on 7 April 2020. Beginning on 13 May 2019, the yield curve on U.S. Treasury securities inverted, [1] and remained so until 11 October 2019, when it reverted to normal. [2]
The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. ... Moderna stock fell over 9% on ... (far below the $18.5 billion in sales reported in ...
As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.